Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500317 | 0.87 | SCD (0.54) | PTGS2PTGS1MAPK14ALOX5ALDH1A1 | |
| SCHEMBL5597237 | 0.85 | PTGS2 (0.54) | PTGS2PTGS1MAPK14ALOX5ALDH1A1 | |
| SCHEMBL5698659 | 0.83 | ALOX5 (0.75) | PTGS2PTGS1MAPK14ALOX5ALDH1A1 | |
| SCHEMBL5597026 | 0.83 | PTGS2 (0.53) | PTGS2MAPK14ALOX5ALDH1A1CSNK1A1 | |
| SCHEMBL6448446 | 0.81 | MAPK14 (0.64) | PTGS2PTGS1MAPK14ALOX5ALDH1A1 | |
| SCHEMBL6465182 | 0.81 | SCD (0.56) | PTGS2PTGS1MAPK14ALOX5ALDH1A1 | |
| SCHEMBL5144240 | 0.79 | MAPK14 (0.51) | MAPK14ALOX5ALDH1A1CSNK1A1CSNK1D | |
| SCHEMBL7798253 | 0.79 | CBFB (0.56) | PTGS2PTGS1MAPK14ALOX5ALDH1A1 | |
| SCHEMBL5501473 | 0.78 | PTGS2 (0.50) | PTGS2PTGS1MAPK14ALOX5ALDH1A1 | |
| SCHEMBL7084444 | 0.77 | PTGS2 (0.54) | PTGS2PTGS1MAPK14ALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0833622-B8 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-10-12 | — | — | EP | claimed |
| JP-2004531514-A | — | — | 2004-10-14 | — | — | JP | claimed |
| US-20040044028-A1 | Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | claimed |
| EP-1381369-A1 | USE OF SELECTIVE COX-2 INHIBITORS FOR THE TREATMENT OF URINARY INCONTINENCE | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2004-01-21 | — | — | EP | claimed |
| US-20030211163-A1 | Combination antiviral therapy | PHARMACIA & UPJOHN COMPANY | 2003-11-13 | — | — | US | claimed |
| US-20030199482-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | PHARMACIA CORPORATION | 2003-10-23 | — | — | US | claimed |
| WO-2002080927-A1 | USE OF SELECTIVE COX-2 INHIBITORS FOR THE TREATMENT OF URINARY INCONTINENCE | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2002-10-17 | — | — | WO | claimed |
| EP-0888127-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997029776-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2020-02-20 | — | — | US | disclosed |
| US-20040229803-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2004-11-18 | — | — | US | disclosed |
| EP-1381369-A1 | USE OF SELECTIVE COX-2 INHIBITORS FOR THE TREATMENT OF URINARY INCONTINENCE | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002080927-A1 | USE OF SELECTIVE COX-2 INHIBITORS FOR THE TREATMENT OF URINARY INCONTINENCE | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2002-10-17 | — | — | WO | disclosed |
| US-6342510-B1 | ANTIINFLAMMATORY AGENTS AND ENZYME INHIBITORS | G. D. SEARLE & CO. | 2002-01-29 | — | — | US | disclosed |
| EP-0880504-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997027181-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211163-A1 | Combination antiviral therapy | EIF2AK2, ZC3HAV1, VHL | PTGS2 1846/4885PTGS1 1821/4885MAPK14 4390/4885 |
| US-20040044028-A1 | Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer | PTGES3, PTGER3, PTGES2 | PTGS2 8/4885PTGS1 15/4885MAPK14 1364/4885 |
| US-20030199482-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | HMGCR, HMGB2, HMGB3 | PTGS2 7/4885PTGS1 18/4885MAPK14 2231/4885 |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | PTGS2 24/4885PTGS1 11/4885MAPK14 1395/4885 |
| US-20040229803-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders | KCNJ2, KCNK2, TRPV2 | PTGS2 21/4885PTGS1 51/4885MAPK14 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.